| INTRODUC TI ON
The concepts and practical considerations for kidney paired donation (KPD) were suggested more than 3 decades ago when living kidney transplant was almost exclusively performed between biological relatives.
1 During the past 3 decades, the practice of live donor kidney transplant between spouses and unrelated individuals has matured and become standard practice in virtually all transplant centers. 2 A number of additional advances have made the clinical practice of exchanging kidneys between patients in different transplant centers commonplace. The major pieces that needed to be tested and validated were the successful outcomes obtained when unrelated donors and recipients exchange kidneys and the ability to safely preserve and ship living donor kidneys over distances sufficient to permit exchanges between multiple geographic regions. [3] [4] [5] [6] [7] The National Kidney Registry (NKR) is a voluntary network currently with 83 transplant centers in 32 US states that is focused on the timely transplant of live donor kidneys through the use of novel computational algorithms that facilitate exchanges of kidneys between member centers. At the current time, this consortium has performed the largest number of KPD transplants in the United States.
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Important questions to ask as kidney paired exchange continues to grow are, precisely who is entered into these networks, and who are the donors and recipients actually being transplanted? The primary indications for KPD are ABO incompatibility (ABOi) and/or lymphocytotoxic crossmatch reactivity. [3] [4] [5] [6] [7] In addition, a smaller but growing number of patients are compatible pairs who are seeking anatomic, physiologic, or immunologic advantage from a paired exchange. 9 Another question to explore at this time is whether KPD transplants are favoring one demographic group over another. On a national level, the transplant of a kidney between a donor and a recipient is governed by a set of rules that is intended to emphasize medical criteria, safety, equity, and ethical constructs. [10] [11] [12] We focus on these questions in an effort to identify whether unintended consequences have emerged in patient selection during kidney paired exchange.
| ME THODS AND MATERIAL S

| The NKR
In this study, the authors used data from the NKR, which is a nonprofit, 501c organization composed of 76 transplant centers within the United States that were participating during the study period.
The NKR policies are available online. 
| Scientific Registry of Transplant Recipients
This study also included data from the Scientific Registry of Transplant 
| Data linkage
Data from KPD transplants facilitated through the NKR reported in the registry were linked to the SRTR data and cross-validated by using encrypted unique identifiers, transplant center, transplant date, donor ABO, donor sex, recipient ABO, and recipient sex.
| Statistical analysis
These study patients were compared with 3 distinct control populations from which the NKR transplants were subtracted. 
Control
| RE SULTS
The annual growth in NKR transplants has continued through the Actuarial 1-, 3-, and 5-year graft survival rates for the NKR transplants and the 3 control groups are provided in Figure 2 . The differences among the groups were not significant at 1 and 3 years.
However, the differences did reach significance (P < .01) at 5 years.
For the NKR transplants, the frequency of primary nonfunction (recipient was never off dialysis) was 0.34% (n = 7) and the frequency of delayed graft function (first week dialysis) was 4.9% (n = 101).
| Recipient characteristics
Recipient and donor demographics are provided in Table 2 compared with the 3 control populations (all UNOS live donors, all UNOS living unrelated donors, other KPD transplants). The NKR recipient median age of 50 years (IQR 39-60) is comparable to that of the controls, while the proportion of women (45.9%) is significantly higher (P < .001) than in the 3 control populations. The NKR transplants had fewer white recipients (60.8%) than did the controls (P < .001).
In particular, the proportion of black KPD recipients (18.2%) was significantly larger (P < .001) than that of the control proportions (13%, 11.7%, and 13.4%, respectively). The proportion of NKR Hispanic recipients (11.5%) was somewhat less than the total UNOS living donor transplant recipients (14.7%) but similar to the other controls. The NKR recipients represented a significantly (P < .001) increased proportion of retransplants 25.6% compared with the controls (11.5%, 12.3%, and 17.1%, respectively) but a similar proportion of preemptive 
| Donor characteristics
Donor demographics are also provided in Table 2 
| NKR transplants
The NKR transplants were performed on a significantly greater proportion of HLA hyperimmunized patients ( Figure 3 and Table 1 ).
Only 45.8% of the NKR recipients had a pretransplant cPRA of 0%, while the control populations represented 71.3%, 71%, and 60% unsensitized recipients (P < .001). The NKR transplants representing the hard-to-match cPRA ranges of 80% to 97% were accomplished for 15.3% of the recipients, while the 3 controls represented only 3%, 3.1%, and 6.9% (P < .001). Only 0.8% of the NKR transplants were between 0 HLA mismatched pairs, which was significantly fewer than all UNOS living donor transplants (7.3%, P < .001). The NKR transplants representing the extremely hard-to-match cPRA >98% were accomplished for 7.4% of the recipients, while the 3 controls represented only 1.3%, 1.1%, and 2.9% (P < .001). In summary, 22.7% of the NKR transplants were performed in hard-and/or extremely hard-to-match recipients, recalling that these patients had not received a 0 mismatched deceased donor kidney from the UNOS national sharing program as well.
Among the 2037 NKR transplants, 11.7% were reported to have undergone desensitization at the transplant centers─222 for donorspecific crossmatch activity and 17 for ABOi. The treatments used for desensitization are represented in Table 3 . While intravenous immunoglobulins and plasmapheresis were the most common interventions, the doses and timing of the various agents used were not recorded in the NKR database. In addition, the stringency of the incompatibilities or the specific posttransplant management protocols used by the centers were not available.
Between the starting and ending dates of this study, there were 59 donor-recipient pairs enrolled and transplanted as compatible pairs. The reasons given for entering paired exchange were to receive a younger kidney (27%), receive a larger kidney (21%), overcome low-level donor-specific antibodies (DSAs) (13%), receive a better HLA match (22%), avoid complex donor kidney anatomy (5%), and help more patients (altruism) (12%). Among the enrolled compatible pairs, 37% were biologically related, 32% were spouses, and 31% Employed, % to enter as a compatible pair, the mean age difference between the paired and actual donors was 23.1 (range 11-42) years. The remaining pairs seeking an anatomic or HLA advantage, or the absence of DSAs, were successfully matched. By entering these compatible pairs, 146 additional transplants were facilitated, and of these, 43
recipients were transplanted with a cPRA >80%.
| Untransplanted patients
When reporting actual KPD results, it is important to identify who was not transplanted once entered into paired exchange. At the end of February 2017, there were 280 unmatched recipients active for transplant. Not surprisingly, the majority were blood group O and were hyperimmunized. The actual distribution was ABO: O (74%), A (14%), B (11%), and AB (1%). Those unmatched by cPRA were for cPRA of 0% (23%), 1% to 79% (22%), 80% to 95% (8%), 95% to 99% (18%), and 100% (29%). A better metric for tracking the accumulation of those recipients difficult to match for transplant may be the number of untransplanted recipients as a percent of those actually transplanted at the end of each calendar year. As provided in Figure 4 , since inception NKR has experienced a peak in unmatched recipients in year 2 (79%) that has fallen but leveled off at 35% to 40% during the past 3 years. In addition, the number of broken chains diminished each year to about 3% annually (Table 4) . These often occur after the logistics for a swap have been made, but intervening conditions such as a change in donor or recipient medical status emerges. Some of these can be repaired by bridging a donor or with advanced donation. 14 The answer to these questions appears to be "no" ( Table 2 States and other parts of the world. 7, [21] [22] [23] [24] In addition, as recently reported in depth, the shipping of kidneys during paired exchange has not been associated with inferior transplant outcomes. 25 Although the number with primary nonfunction (0.34%) was low, the number with first week dialysis (4.9%) is higher than in-center exchanges.
Some have suggested that live donor kidneys older than 55 years may be more susceptible to extra CITs.
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As reported in Figure 3 , the NKR recipients were significantly (P < .001) more sensitized to HLA, perhaps related to the greater numbers of retransplants, than were the controls. Notably, 22.7% of NKR recipients had a cPRA >80%, 7.4% had a cPRA >98%, and 2.5% were both blood group O and had a cPRA >98%. Many of these recipients were unable to find a suitable deceased donor kidney as well. While
HLA sensitization leading to donor-specific crossmatch reactivity is a primary indication to enter paired exchange, it is also a leading indicator of waiting time once enrolled. The NKR has not intentionally limited or discouraged entering highly sensitized recipients into the network. While the number of KPD transplants that were ABOi (2.2%, excluding A2 into O) or were intentionally desensitized (11.7%) were not common, this may be an area for future growth. 27, 28 Some have speculated that the accumulation of hyperimmunized O recipients with non-O donors will overwhelm paired exchange networks, 29 but these concerns appear to be unwarranted ( Figure 4 ).
The unmatched pool of candidates at year's end has in fact declined to about 35% to 40% of those transplanted, although the predominant characteristics of those unmatched candidates were 74% ABO blood type O and 29% cPRA = 100%. While the difficulty to find donors for these hard-to-match recipients has thus far depended on the entry of blood type O nondirected donors for chain initiation, future expansion of KPD via increasing network pool sizes, compatible pair enrollments, 9 the possibility of deceased donor chain initiation, 30 and global sharing 31 may further expand these opportunities.
The limitations of this study are similar to those present in any registry-based analysis. While some data were not collected or lacked granularity, by merging both the national and local (NKR) data sets, we were able to capture a wide array of relevant covariates.
Although such a merge may be redundant for some variables (ie, race, sex, insurance), it reduced missing data to <2% for each category. On a center level, it is not known how many potential KPD patients were evaluated and ultimately excluded based on local medical or psychosocial criteria. There were certainly center-level decisions made for donor acceptance criteria such as the degree of allosensitization or anatomic or physiologic risk:benefit determinations for a particular swap.
In conclusion, the practice of KPD in general and the NKR network in particular is expanding annually, offering the opportunity for compatible live donor kidney transplant to more patients. The demographic and clinical characteristics of those actually transplanted appear similar to contemporary national trends. However, an analysis such as this do not fully capture the enormous number of logistic considerations that need to be accommodated between patients, families, and transplant centers. These results encourage broader sharing and larger pool sizes to unlock more opportunities for harder-to-match pairs.
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